Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
View Patent ↗Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
1. A method of treating pain comprising administering denosumab to relieve osteoarthritis pain in a mammal in need thereof, wherein the mammal has a bone marrow lesion.
2. The method of claim 1 , wherein the denosumab is administered subcutaneously.
3. The method of claim 2 , wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the mammal over a four week period.
4. The method of claim 3 , wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the mammal over a four week period.
5. The method of claim 2 , wherein about 30 mg to about 180 mg of denosumab is administered to the mammal no more than once a week.
6. The method of claim 5 , wherein about 30 mg to about 180 mg of denosumab is administered weekly to the mammal for two to four weeks.
7. The method of claim 2 , wherein about 100 mg to about 140 mg of denosumab is administered to the mammal over a three to five week period.
8. The method of claim 2 , wherein about 120 mg of denosumab is administered to the mammal over a four week period.
9. The method of claim 1 , wherein the denosumab is administered intravenously.
10. The method of claim 1 , wherein the denosumab is administered intramuscularly.
11. The method of claim 1 , wherein the denosumab is administered intradermally.
12. The method of claim 1 , wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the mammal over a four week period.
13. The method of claim 1 , wherein about 1 mg/kg to about 3 mg/kg of denosumab is administered to the mammal over a three to five week period.
14. The method of claim 1 , wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the mammal over a three to five week period.
15. The method of claim 1 , wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the mammal over a four week period.
16. The method of claim 1 , wherein about 120 mg of denosumab is administered to the mammal over a four week period.
17. The method of claim 1 , wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is administered to the mammal.
18. The method of claim 1 , wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is administered to the mammal.
19. The method of claim 1 , wherein the mammal is a human being.
20. The method of claim 1 , wherein the osteoarthritis affects a knee or hip.
21. The method of claim 1 , wherein the osteoarthritis affects an elbow, a shoulder, a wrist, or a finger.